CAJ | 학술논문

目的探讨米诺环素与头孢哌酮/舒巴坦联合应用对多重耐药鲍曼不动杆菌的疗效，为有效治疗多重耐药鲍曼不动杆菌（MDR-ABA）感染提供理论依据。方法常规方法培养分离细菌共54株，获得纯培养后用VITEK-2全自动分析仪鉴定鲍曼不动杆菌，应用纸片扩散法进行多种抗菌药物的药敏试验，确定其中34株为多重耐药鲍曼不动杆菌。随机选取30株采用微量肉汤稀释法测定米诺环素和头孢哌酮/舒巴坦（1︰1）的单药MIC值。再采用棋盘法测定米诺环素和头孢哌酮/舒巴坦（1︰1）的联用MIC值。计算FIC指数并进行相关统计学分析。结果米诺环素与头孢哌酮/舒巴坦联合应用FIC指数0～0.5者占35.3%，0.5～1者占58.8%，1～2者占5.9%。结论米诺环素与头孢哌酮/舒巴坦联合应用具有协同和叠加作用，二者之间无拮抗作用，临床上治疗由MDR-ABA引起的重症感染，可根据药敏试验结果选择联合用药。
목적탐토미낙배소여두포고동/서파탄연합응용대다중내약포만불동간균적료효，위유효치료다중내약포만불동간균（MDR-ABA）감염제공이론의거。방법상규방법배양분리세균공54주，획득순배양후용VITEK-2전자동분석의감정포만불동간균，응용지편확산법진행다충항균약물적약민시험，학정기중34주위다중내약포만불동간균。수궤선취30주채용미량육탕희석법측정미낙배소화두포고동/서파탄（1︰1）적단약MIC치。재채용기반법측정미낙배소화두포고동/서파탄（1︰1）적련용MIC치。계산FIC지수병진행상관통계학분석。결과미낙배소여두포고동/서파탄연합응용FIC지수0～0.5자점35.3%，0.5～1자점58.8%，1～2자점5.9%。결론미낙배소여두포고동/서파탄연합응용구유협동화첩가작용，이자지간무길항작용，림상상치료유MDR-ABA인기적중증감염，가근거약민시험결과선택연합용약。
Objective To study the drug resistance and antibacterial in vitro of multi-drug resistant Acinetobacter baumannii (MDR-ABA) against minocycline combined with cefoper azone/sulbactam in order to provide laboratory data for clinical treatment. Method Total of 54 strains were isolated and identiifed by routine procedure and VITEK-2 automatic bacterial identification instrument. Totally, 34 strains were identified as MDR-ABA by the disk diffusion method. And 30 strains with random selection were determined as single drug minocycline and cefoperazone/sulbactam (1︰1) MIC values by the broth micro-dilution method. Checkerboard method was applied to determine the MIC values of combination of minocycline and cefoperazone/sulbactam (1︰1). The FIC index was calculated and relevant statistical analysis was carried out. Results FIC index 0-0.5 of minocycline and cefoperazone/sulbactam combination accounted for 35.3%, 0.5-1 accounted for 58.8%, 1-2 accounted for 5.9%. Conclusions Combined with minocycline, cefoperazone-sulbactam expresses synergism and additivity against multi-drug resistant Acinetobacter baumannii and there is no antagonism.